REBOOT- Combination of Belimumab with Rituximab for Primary MN
Brief description of study
The main purpose of this study is to learn if the combination of belimumab and rituximab
treatment is more effective in making and keeping Primary MN inactive compared totreatment with rituximab alone.
This is a three-year research study for people with primary membranous nephropathy
(Primary MN). The study may require up to 24 clinic visits over the three years of the study. The study will test if combining belimumab and rituximab is more effective in treating
Primary MN vs. rituximab alone. Study participants will have procedures that are not part of a routine doctor’s visit.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
primary membranous neuropathy,neuropathy
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 833872
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
